658 related articles for article (PubMed ID: 17173284)
1. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
2. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
Verkhivker GM
Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
[TBL] [Abstract][Full Text] [Related]
3. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
Verkhivker GM
Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a RET TK catalytic domain by homology modeling.
Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
[TBL] [Abstract][Full Text] [Related]
5. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
7. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
Verkhivker GM
Bioinformatics; 2006 Aug; 22(15):1846-54. PubMed ID: 16720585
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
9. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
12. In silico drug profiling of the human kinome based on a molecular marker for cross reactivity.
Zhang X; Fernández A
Mol Pharm; 2008; 5(5):728-38. PubMed ID: 18620417
[TBL] [Abstract][Full Text] [Related]
13. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.
Trumpp-Kallmeyer S; Rubin JR; Humblet C; Hamby JM; Showalter HD
J Med Chem; 1998 May; 41(11):1752-63. PubMed ID: 9599227
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
15. A priori inference of cross reactivity for drug-targeted kinases.
Fernandez A; Maddipati S
J Med Chem; 2006 Jun; 49(11):3092-100. PubMed ID: 16722629
[TBL] [Abstract][Full Text] [Related]
16. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
[TBL] [Abstract][Full Text] [Related]
17. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine kinase-substrate interactions.
Bose R; Holbert MA; Pickin KA; Cole PA
Curr Opin Struct Biol; 2006 Dec; 16(6):668-75. PubMed ID: 17085043
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol CD; Fabbro D; Hosfield DJ
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
